YCYotin Chinvarun

Yotin Chinvarun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yotin Chinvarun has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiorespiratory cross‐frequency coupling biomarker for sudden unexpected death in epilepsy

    by Adam C. Gravitis, Richard Wennberg, Peter L. Carlen, Yotin Chinvarun, Victor Lira, Juliana Laze, Orrin Devinsky, Berj L. Bardakjian

    Objective: Sudden unexpected death in epilepsy (SUDEP) often follows generalized tonic–clonic seizures during sleep, likely resulting from impaired brainstem cardiorespiratory function. We used ictal electrocardiogram (ECG)‐based cross‐frequency phase–amplitude coupling (PAC) to detect cardiorespiratory disruptions, comparing SUDEP to non‐SUDEP cohorts. Leveraging respiratory modulation of ECG signals can provide a robust indirect proxy of respiratory monitoring despite high‐amplitude noise. Methods: We analyzed ictal ECG and electroencephalographic recordings in 21 SUDEP cases and 21 non‐SUDEP epilepsy controls. Ictal ECG segments from 76 seizures (38 SUDEP, 38 non‐SUDEP) were processed using continuous wavelet transformation to compute PAC between respiratory (.1–.55 Hz, 6–33 breaths per minute) and cardiac (.7–3.7 Hz, 42–222 beats per minute) frequencies. Relative PAC coupling strength was evaluated for respiratory frequencies > .25 Hz (15 breaths per minute) and cardiac frequencies > 1.7 Hz (102 beats per minute). Furthermore, a 3 × 3 grid of PAC ranges was derived for each 20‐s window, yielding 18 features (mean and SD) as inputs to a logistic regression model. Results: Elevated ictal PAC at higher respiratory (>.25 Hz, p < .0001) and cardiac (>1.7 Hz, p < .0142) frequencies in SUDEP patients suggests ictal respiration modulates ictal tachycardia, leading to cardiorespiratory dysfunction, probably brainstem‐mediated. The logistic model accurately distinguished 38 seizures in SUDEP cases from 38 seizures in non‐SUDEP cases (receiver operating characteristic area under the curve = 91%). Seizures in SUDEP patients had higher propensity scores ( p < .001) both per seizure and per patient. All six test seizures (three SUDEP, three non‐SUDEP) were correctly classified using the optimal threshold. Significance: Ictal ECG‐based PAC analysis is a potential noninvasive biomarker for SUDEP risk, capturing cardiorespiratory dysregulation during seizures. Its integration into wearable ECG devices could enable real‐time risk assessment, informing clinical interventions such as rescue medications, antiseizure medication adjustments, or surgical evaluations.


  • Open Access

    Perampanel Monotherapy for Focal and Generalized Epilepsy in Clinical Practice

    by Yotin Chinvarun, Rafael Toledano Delgado, Alexandra Astner-Rohracher, Tim Wehner, Manuel Toledo, Sara Matricardi, Eugen Trinka, Manoj Malhotra, Oliver Shastri, Vicente Villanueva

    Objectives. To investigate the effectiveness, safety, and tolerability of perampanel (PER) when used as monotherapy to treat focal or generalized epilepsy in everyday clinical practice, using data from the PERMIT study. Methods. PERMIT was a pooled analysis of 44 real-world studies from 17 countries, in which people with focal and generalized epilepsy were treated with PER. This post hoc analysis included people with epilepsy (PWE) from PERMIT who were treated with PER monotherapy at baseline. Retention and effectiveness were assessed after 3, 6, and 12 months. Effectiveness assessments included 50 responder rate and seizure freedom rate (no seizures since at least the prior visit). Safety and tolerability were assessed by evaluating adverse events (AEs) and discontinuation due to AEs. Results. Overall, 268 PWE were treated with PER monotherapy at baseline. Retention was assessed for 168 PWE, effectiveness for 183 PWE, and safety and tolerability for 197 PWE. Retention rates were 91.1, 87.3, and 73.3 at 3, 6, and 12 months, respectively. At 12 months, responder rates were 84.2 overall, 82.9 in PWE with only focal-onset seizures at baseline, and 88.0 in those with only generalized-onset seizures at baseline; corresponding freedom rates were 62.9, 57.7, and 80.0, respectively. AEs were reported for 45.2 of PWE. The most frequently reported AEs (5 of PWE) were dizziness/vertigo (16.8), irritability (11.2), somnolence (9.1), and depression (6.6). Over 12 months, 13.7 discontinued due to AEs. Conclusions. PER was effective when used as monotherapy in clinical practice, particularly in those with generalized-onset seizures, and was generally well tolerated.


  • Open Access

    A retrospective, real‐world experience of perampanel monotherapy in patient with first new onset focal seizure: A Thailand experience

    by Yotin Chinvarun

    Objective: Real‐world data on efficacy and tolerability of perampanel (PER) monotherapy in treatment‐naïve patients with focal onset seizures (FOS) and/or focal‐to‐bilateral tonic‐clonic seizures (FBTCS) to assess efficacy effectiveness and tolerability.Methods: This is a retrospective review of study patients with new FOS with or without FBTCS, aged ≥15 years, who had been prescribed PER as monotherapy. Treatment outcome included retention rate, responder, and seizure‐free rate at observational point 3, 6, and 12 months (OP3, OP6, and OP12). Treatment‐emergent adverse events (TEAEs) and adverse drug reactions were recorded.Results: A total of 41 patients enrolled in the study (male:female; 17:22, mean age =46.1 ± 21.8 years), with new FOS and/or FBTCS. The proportions of individuals remaining on PER monotherapy at 3, 6, and 12 months were evaluated. The median PER dosage was 4 mg (range 2‐8 mg). The retention rates at OP3, OP6, and OP12 were 88%, 73%, and 61%, respectively. The seizure freedom rates at OP3, OP6, and OP12 were 78%, 80%, and 76%, respectively. About 14% had discontinued the PER monotherapy because of lack of efficacy. Sixteen individuals (41%) had TEAEs; common AEs were dizziness, somnolence, and ataxia; and only one case had depression. The AEs with somnolence and ataxia were found higher in elderly (15% and 30%) than adult patients (7% and 3%), respectively. Only 14% had intolerant adverse events, and it was found higher in elderly (23%).Significance: Real‐world data of PER monotherapy in treatment‐naïve patients with focal onset seizures demonstrated good effectiveness and a good safety profile at relatively low doses. By starting with low dosage and slow titration of PER help to minimize the impact of adverse effects, maximize adherence, and increase patient retention. PER has a once‐daily dosing schedule that supports patient adherence contributes to achieving seizure freedom.


  • Depression in people with epilepsy: How much do Asian colleagues acknowledge it?

    by Ali A. Asadi-Pooya, Kousuke Kanemoto, Oh-Young Kwon, Go Taniguchi, Zhou Dong, Yotin Chinvarun, Hsiang-Yu Yu, Aileen McGonigal, Andres Miguel Kanner, Sung-Pa Park


  • Identification of brain regions of interest for epilepsy surgery planning using support vector machines

    by Joshua A. Dian, Sinisa Colic, Yotin Chinvarun, Peter L. Carlen, Berj L. Bardakjian

    In patients with intractable epilepsy, surgical resection is a promising treatment; however, post surgical seizure freedom is contingent upon accurate identification of the seizure onset zone (SOZ). Identification of the SOZ in extratemporal epilepsy requires invasive intracranial EEG (iEEG) recordings as well as resource intensive and subjective analysis by epileptologists. Expert inspection yields inconsistent localization of the SOZ which leads to comparatively poor post surgical outcomes for patients. This study employs recordings from 6 patients undergoing resection surgery in order to develop an automated and scalable system for identifying regions of interest (ROIs). Leveraging machine learning techniques and features used for seizure detection, a classification system was trained and tested on patients with Engel class I to class IV outcomes, demonstrating superior performance in the class I patients. Further, classification using features based upon both high frequency and low frequency oscillations was best able to identify channels suited for resection. This study demonstrates a novel approach to ROI identification and provides a path for developing tools to improve outcomes in epilepsy surgery.